{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:56:53Z","timestamp":1778770613330,"version":"3.51.4"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals\u2019 Ascent Plan","doi-asserted-by":"crossref","award":["DFL20180701"],"award-info":[{"award-number":["DFL20180701"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Primary peritoneal epithelioid mesothelioma of clear cell type is an extremely rare entity composed of clear cytoplasm. It is challenging to diagnose because of the morphological resemblance to clear cell tumor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient's concerns:<\/jats:title>\n            <jats:p>A 69-year-old male patient had swollen lymph nodes in the right inguinal region for 7\u200amonths and was constipated for 1\u200amonth.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The patient was diagnosed as peritoneal epithelioid mesothelioma of clear cell type based on computed tomography scan, pathology, immunohistochemistry, special staining and whole-exome sequencing. This patient harbored <jats:italic toggle=\"yes\">VHL<\/jats:italic> gene alteration in exon 1 and homologous recombination defect (with a score of 45). This finding indicated that this patient might be sensitive to platinum-based therapy and Poly ADP-ribose Polymerase (PARP) inhibitor. This patient carried no microsatellite instability, a low level of tumor mutation burden, and a high extent of intratumoral heterogeneity. Eighteen neoantigens were detected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient received surgery-based multidisciplinary treatment by integrating cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). HIPEC was administered with docetaxel 120\u200amg plus cisplatin 120\u200amg, at 43\u00b0C, for 60 minutes. After operation, the patient received intravenous (IV) chemotherapy with docetaxel 60\u200amg, pemetrexed 750\u200amg and cisplatin 100\u200amg, and then intraperitoneal (IP) chemotherapy with docetaxel 40\u200amg. The patient received interventional therapy of hepatic artery embolization for 5 times.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Regular follow-up was performed until Oct 14, 2020. The patient died 31.6\u200amonths later owing to incomplete intestinal obstruction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Primary peritoneal epithelioid mesothelioma of clear cell type needs to be differentiated from a variety of clear cell tumors. This disease is characterized by specific genetic alteration. Whole-exome sequencing contributes to guide individualized therapy. CRS-HIPEC helps achieve long-term overall survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025264","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T19:45:04Z","timestamp":1616528704000},"page":"e25264","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Clinicopathological characteristics of primary peritoneal epithelioid mesothelioma of clear cell type"],"prefix":"10.1097","volume":"100","author":[{"given":"Xue-Mei","family":"Du","sequence":"first","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Ping","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Mei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-6538","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10552-009-9328-9","article-title":"Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973\u20132005","volume":"20","author":"Moolgavkar","year":"2009","journal-title":"Cancer Causes Control"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","article-title":"Introduction to the 2015 world health organization classification of tumors of the lung, pleura, thymus, and heart","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.humpath.2005.02.014","article-title":"Mesothelioma with clear cell features: an ultrastructural and immunohistochemical study of 20 cases","volume":"36","author":"Ord\u00f3\u00f1ez","year":"2005","journal-title":"Hum Pathol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.5858\/2001-125-1588-UCCVOE","article-title":"Unusual clear cell variant of epithelioid mesothelioma","volume":"125","author":"Dessy","year":"2001","journal-title":"Arch Pathol Lab Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"8759","DOI":"10.7314\/APJCP.2014.15.20.8759","article-title":"Distribution of Ki67 proliferative indices among WHO subtypes of non-Hodgkin's lymphoma: association with other clinical parameters","volume":"15","author":"Hashmi","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.oraloncology.2012.09.007","article-title":"MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma","volume":"49","author":"Mroz","year":"2013","journal-title":"Oral Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/01913129609016333","article-title":"Clear cell mesothelioma","volume":"20","author":"Ord\u00f3\u00f1ez","year":"1996","journal-title":"Ultrastruct Pathol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00428-005-0023-2","article-title":"Clear cell mesothelioma presenting as an incarcerated abdominal hernia","volume":"447","author":"Ord\u00f3\u00f1ez","year":"2005","journal-title":"Virchows Arch"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/1066896913520037","article-title":"Peritoneal malignant mesothelioma metastatic to supraclavicular lymph nodes","volume":"22","author":"Zannella","year":"2014","journal-title":"Int J Surg Pathol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.prp.2016.12.025","article-title":"Malignant peritoneal mesothelioma, clear cell variant, in a female and its differentiation from clear cell carcinoma","volume":"213","author":"Hayashi","year":"2017","journal-title":"Pathol Res Pract"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.humpath.2018.07.033","article-title":"Primary peritoneal epithelioid mesothelioma of clear cell type with a novel VHL gene mutation: a case report","volume":"83","author":"Smith-Hannah","year":"2019","journal-title":"Hum Pathol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5858\/arpa.2017-0092-OA","article-title":"Immunohistochemistry in peritoneal mesothelioma: a single-center experience of 244 cases","volume":"142","author":"Tandon","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N Engl J Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the international mesothelioma interest group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5858\/arpa.2015-0240-SA","article-title":"New markers for separating benign from malignant mesothelial proliferations: are we there yet?","volume":"140","author":"Churg","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2014.08.004","article-title":"Identification of actionable mutations in malignant pleural mesothelioma","volume":"86","author":"Shukuya","year":"2014","journal-title":"Lung Cancer"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J Clin Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","article-title":"Treatment factors associated with long term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma","volume":"153","author":"Alexander","year":"2013","journal-title":"Surgery"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","article-title":"Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis","volume":"21","author":"Magge","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1245\/s10434-018-6499-1","article-title":"Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival","volume":"25","author":"Verma","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1245\/s10434-015-4498-z","article-title":"Immunohistochemical evaluation of minichromosome maintenance protein 7 (MCM7), Topoisomerase II\u03b1, and Ki-67 in diffuse malignant peritoneal mesothelioma patients using tissue microarray","volume":"22","author":"Deraco","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.copbio.2017.03.024","article-title":"Personalized T cell-mediated cancer immunotherapy: progress and challenges","volume":"48","author":"Bethune","year":"2017","journal-title":"Curr Opin Biotechnol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"Mcgranahan","year":"2016","journal-title":"Science"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/17476348.2019.1563488","article-title":"Immunotherapy strategies for mesothelioma - the role of tumor specific neoantigens in a new era of precision medicine","volume":"13","author":"Ye","year":"2019","journal-title":"Expert Rev Respir Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:28:57Z","timestamp":1746340137000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025264"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025264","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"2020-12-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}